Natural steroids and their synthetic congeners were extensively studied during the last decade (1, 2). In a previous work, some new heterocyclic compounds showing antiparkinsonian (3), antitumor (4-6), antimicrobial (7-10) and anti-inflammatory (11) activity were synthesized. We found that certain substituted steroidal derivatives showed androgenic, anabolic and anti-inflammatory activities (12). Steroidal pyrazolines are an interesting group of compounds, many of which possess wide spread pharmacological properties such as analgesic, antipyretic and antiandrogenic activities (13, 14) . These derivatives are also well known for their pronounced anti-inflammatory (15) activity and are used as potent antidiabetic agents (16). In addition, the pharmacological and antitumor activities of many heterocyclic compounds have been reviewed (17) (18) (19) . Recently, nitrogenous derivatives exhibited a general ionophoric potency for divalent cations (20) and are used as novel thiocyanate-selective membrane sensors (21). In view of these reports and in continuation of our previous work in heterocyclic chemistry, we have herein synthesized some new compounds containing steroidal structure for the evaluation of androgenic-anabolic activity as compared to testosterone as standard drug (Fig.  1) . Accepted February 5, 2008 In this study, we synthesized some new substituted steroidal derivatives using 3b-hydroxyandrosten-17-one (dehydroepiandrosterone) as starting material. The synthesized steroidal derivatives 1-11 were evaluated for their androgenic-anabolic activities compared to testosterone as positive control. Details of the synthesis, spectroscopic data and toxicity (LD 50 ) of synthesized compounds are reported.
water and dried over anhydrous sodium sulphate. The benzene part was evaporated under reduced pressure and the residue obtained was solidified with n-hexane. The obtained solid was filtered off, dried and crystallized from the proper solvent to give the derivatives 2a,b, respectively (Scheme 1).
Synthesis of 17b-cyano-17a-[N-methyl-N-(piperidin-1-ylmethyl)amino]androst-5-en-3b-ol (3a) and 17b-cyano-17a-[N-phenyl-N-(piperidin-1-ylmethyl)amino]androst-5-en-3b-ol (3b)
A mixture of carbonitrile derivatives 1a,b (1 mmol) and piperidine (4 mmol) was refluxed for 2 hours in the presence of powdered paraformaldehyde (12 mg) in 1% hydrochloric acid in ethanol (15 mL). The reaction mixture was concentrated under reduced pressure to dryness; the solid formed was collected by filtration, washed with ethanol, dried and crystallized from the proper solvent to afford the corresponding piperidenyl derivatives 3a,b, respectively (Scheme 1). 
Synthesis of 17b-cyano-17a-(N-methylacetamido)-androst-5-en-3b-acetate (4a), 17b-cyano-17a-(N-phenylacetamido)-androst-5-en-3b-acetate (4b), 17b-cyano-17a-(N-methyl-trifluoroacetamido)-androst-5-en-3b-trifluoroacetate (5a) and 17b-cyano-17a-(N-phenyl-trifluoroacetamido)-androst-5-en-3b-trifluoroacetate (5b)
A solution of compounds 1a,b (150 mg) in acetyl chloride or trifluoroacetic anhydride (5 mL) was stirred at room temperature for 24 hours. The reaction mixture was poured into ice-water, the separated solid was filtered off, dried and crystallized from the proper solvent to yield the compounds 4a,b and 5a,b, respectively (Scheme 2).
Synthesis of 17b-aminomethyl-17a-(N-methyl)-androst-5-en-3b-ol (6a), 17b-aminomethyl-17a-(N-phenyl)-androst-5-en-3b-ol (6b), 17b-aminomethyl-17a-(N-methyl)-androstan-3b-ol (7a) and 17b-aminomethyl-17a-(N-phenyl)-androstan-3b-ol (7b)
A mixture of compounds 1a,b (5 mmol) and catalytic reagents, namely, palladium--charcoal or platinum oxide-charcoal (Adam's catalyst) (50 mg) in absolute ethanol (25 mL) was shaken at 75°C under hydrogen (5´10 5 Pa) for 7 hours and filtered. The filtrate was evaporated under reduced pressure, the residue was solidified with ether, the separated solid was filtered off, dried and crystallized from the proper solvent to yield the compounds 6a,b and 7a,b, respectively (Scheme 2). 
Synthesis of 3b-hydroxy-17a-methyl amino-androst-5-ene-17b-carboxamide (8a) and 3b-hydroxy-17a-phenyl amino-androst-5-ene-17b-carboxamide (8b)
A solution of compounds 1a,b (1 mmol) in sulphuric acid (0.5 mol L -1 , 10 mL) was heated at 50°C for 5 hours, then left overnight at room temperature. The reaction mixture was poured into ice water, the separated product was filtered off, washed with water, dried and crystallized from the proper solvent to give the corresponding carboxamide derivatives 8a,b, respectively (Scheme 3).
Synthesis of 3b-hydroxy-17a-methyl amino-androst-5-ene-17b-carboxylic acid (9a) and 3b-hydroxy-17a-phenyl amino-androst-5-ene-17b-carboxylic acid (9b)
A mixture of compounds 1a,b (1 mmol) in alcoholic sodium hydroxide (25 mL, 10%) was refluxed for 7 hours. The reaction mixture was acidified with 1 mol L -1 hydrochloric acid (pH~3). The separated product was filtered off, washed with water, dried and crystallized from the proper solvent to give the corresponding acid derivatives 9a,b, respectively (Scheme 3).
Synthesis of 3-oxo-17a-methyl amino-androst-5-ene-17b-carboxylic acid (10a) and 3-oxo-17a-phenyl amino-androst-5-ene-17b-carboxylic acid (10b)
A mixture of compounds 1a,b (2 mmol) and Killian reagent (6 mL) [prepared from potassium dichromate (6 g) and concentrated sulfuric acid (8 mL) in water (27 mL)] in glacial acetic acid (15 mL) was stirred at room temperature for 1.5 hours. The reaction mixture was warmed with methanol (15 mL) to destroy excess chromic acid, then it was poured into ice-water; the solid formed was filtered off, washed with water, dried and crystallized from the proper solvent to give 3-oxo-17-substituted amino-androst-5-ene-17-carboxylic acids 10a,b, respectively (Scheme 3).
Synthesis of 17a-(2-imidazolyl)-17b-methyl amino-androst-5-ene-3b-ol (11a) and 17a-(2-imidazolyl)-17b-phenyl amino-androst-5-en-3b-ol (11b)
A mixture of compounds 1a,b (1 mmol) in ethylene diamine (15 mL) was refluxed for 3 hours. The reaction mixture was poured into water, the formed solid was filtered off and crystallized from the proper solvent to give the corresponding imidazole derivatives 11a,b, respectively (Scheme 3).
Biological screening
Animals. -Biological experiments were made according to the ethical rules and animals were obtained from the animal house colony of the National Research Center, Cairo, Egypt. All animals were allowed free access to water and were kept on a constant standard diet. Prepubertal Sprague-Dawley male albino rats 21 day old (45-50 g), were used to investigate the effect of the tested compounds on the development of male sex organs. Adult male albino rats (150 days) weighting (150-200 g) were used in the present work to evaluate the androgenic-anabolic activity of all newly synthesized derivatives.
Acute toxicity (LD 50 )
Male rats were used to determine intraperitoneal LD 50 of the tested compounds. Prior to determination of the LD 50 value, a range finding screen was conducted using 20 rats each treat with a tested compound at a dose ranging from 3-2000 mg kg -1 . Based on the mortality observed within 14 days, the doses used for the LD 50 determination were 3, 10, 30, 100, 300, 1000, 2000 mg kg -1 for compounds administered by intraperitoneal injection as a 10% solution in dimethyl sulphoxide (DMSO). Control animals received intraperitoneal injections of DMSO. For each concentration and control, ten male rats were injected with the tested compounds twice daily for two weeks to kill any swirved animals. From the mortality data of all tested animals, the intraperitoneal LD 50 values for each agent were determined according to Austen et al. (22) (Table III) . 
Androgenic-anabolic activity
Groups of immature male albino rats (each group contains 8 animals), 21 days old, received subcutaneously particular target compounds and testosterone as reference standard at a total dose of 0.7 mg kg -1 according to the following design: group 1 received the vehicle (DMSO); group 2 received the testosterone reference standard in vehicle (DMSO) (at a dose of 0.1 mg kg -1 daily for 7 days); group 3 was subdivided into 22 subgroups, each received individually one of the tested compounds (at a dose of 0.1 mg kg -1 daily for 7 days).
Androgenic-anabolic activity of all newly synthesized compounds was measured according to the reported procedure (23, 24) (Tables IV and V) . Groups of prepubertal albino rats (n = 8) 21 days old, were kept on a constant diet and tap water. Each animal was given daily a subcutaneous injection of the tested compound as well as testosterone as reference standard at a dose of 0.1 mg kg -1 for seven days. On day eight (22-26 hours after the last injection), the animals were killed, dissection of the levator ani muscle, the ventral prostate gland, testis, seminal vesicles, vas deference and epididymis were carried out and were weighed.
The ratio of the mass gain of the levator ani-muscle to the mass gain of the ventral prostate gland was calculated where the mass gain of the levator ani muscle indicates the anabolic effect and the mass gain of the ventral prostate gland shows the androgenic effect of the tested compounds.
RESULTS AND DISCUSSION
In the present work, we utilized Strechker synthesis to introduce the 17b-cyano--17a-substituted amino group into synthesized compounds, because the cyano group provides a wide variety of biological activities. Amino group serves to form water-soluble salts that increase the pharmacokinetics and pharmacodynamics of steroids such as Stanazolole ® due to its increased absorption and distribution in plasma protein. Killian's catalyst Scheme 3 th 1,2-diaminoethane gave the corresponding imidazole derivatives 11a,b. The IR spectra of 8-11 showed the absence of bands corresponding to n(CºN) for 1 and the presence of bands corresponding to n(C=O) for compounds 8-10 and n(NH) for 11. The syntheses of compounds 8-11 are outlined in Scheme 3.
Acute toxicity
Initially, acute toxicity of the synthesized compounds was assayed by determining their LD 50 . Interestingly, most compounds were less toxic than the reference drug, except compounds 1b, 4b, 6a, 7b and 8b (Table III) . The LD 50 (rats) was determined by injecting different increasing doses and calculating the dose that killed 50% of the animals.
Androgenic-anabolic activity
The newly synthesized compounds were then pharmacologically screened for their androgenic-anabolic potency on male albino rats.
From Tables IV and V, the ratio of the mass gained by the levator ani-muscle to the mass gained by the prostate gland was calculated, where the former indicates the anabolic activity and the latter shows the androgenic effect of the tested compounds. It was revealed that all the tested compounds have significant androgenic as well as anabolic effects. Regarding the androgenic activity indicated by the mass gained by the prostate gland, compounds 3a, 6b-11b showed high androgenic activity.
Compounds 1a, 1b, 2a, 2b, 3b, 4a, 4b, 5a and 5b showed potent anabolic activities where the ratio of mass gained by the levator ani-muscle (anabolic) to the mass gained by the ventral prostate were 2.20, 1.90, 1.82, 1.28, 1.09, 1.08, 1.68, 2.30 and 1.06 (Table IV) .
It is evident from Table V that compounds 3a, 6b-11b significantly increase the mass of male sex organs. Compound 5a showed high anabolic activity, increasing the mass of both levator-ani muscle and prostate gland in a statistically significant manner. It increased the mass of the testicles but in a non-significant manner.
Structure activity relationship (SAR)
The presence of some groups (hydrogen bond donors) is beneficial for androgenic activities. The activity was found to decrease in the following order: 6a, 6b, 8a, 7b, 11b and 7a. It was found that the anabolic activity was decreasing in the order: 5a, 1a, 1b, 4b, 2a, 3b, 4a and 5b, indicating that the presence of hydrogen bond acceptor is an important beneficial factor for anabolic activity.
CONCLUSIONS
Twenty-two steroidal derivatives were synthesized and tested for their androgenic--anabolic activities. The substituted steroidal structure containing 5-ene double bonds was found essential for androgenic-anabolic activity. A future work will involve the design of steroidal molecules of such features.
